近日,来自米利亚姆医院的研究者运用一种新的综合分析技术分析表明,II型糖尿病病人存在20%患血癌的风险,比如非霍奇金淋巴瘤、白血病和骨髓瘤。这项研究刊登在了国际著名杂志Blood上,研究数据为糖尿病和特定类型的癌症之间的联系提供了证据。
研究者Jorge Castillo表示,大多数人只认为心脏疾病、肾衰竭和糖尿病直接相关,然而在超过1900万被诊断患有糖尿病的美国人中患血癌等风险比例提高了20%。以前的研究表明,糖尿病和肝癌、胰腺癌有关系,很少有研究揭示血癌和糖尿病之间的关系。
研究者分析了26篇科学家发表的关于II型糖尿病和淋巴瘤、白血病关系的相关研究论文,而后研究者又对时间范围内超过17000名II型糖尿病患者和血癌患者进行整合分析。最后总结道,II型糖尿病患者患白血病、骨髓瘤以及非霍奇金淋巴瘤的风险明显增加,更有意思的是,研究者发现患淋巴瘤、骨髓瘤以及白血病的患者会因地区不同,其发病风险也不尽相同,比如,非霍奇金淋巴瘤在亚洲和欧洲比较高发,而白血病在美国和亚洲比较高发。
研究并没有发现为什么II型糖尿病为什么和这些疾病相关,研究者表示,他们后期还会进行一些深入研究来解释II型糖尿病和血癌之间的潜在关系。Castillo后期会重点研究肥胖、物理活动、抽烟相关的行为因素,这些都和糖尿病、癌症有一定的关系。相关研究由国立卫生研究院提供资助。(生物谷Bioon.com)
编译自:Type 2 Diabetes Linked to Increased Blood Cancer Risk
编译者:T.Shen
doi:10.1182/blood-2011-06-362830
PMC:
PMID:
Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies
Jorge J. Castillo1, Nikhil Mull2, John L. Reagan1, Saed Nemr2, and Joanna Mitri3
Hematologic malignancies are a heterogeneous group of conditions with an unclear etiology. We hypothesized that diabetes mellitus type 2 is associated with increased risk of developing lymphoma, leukemia, and myeloma. A literature search identified 26 studies (13 case-control and 13 cohort studies) evaluating such an association. Outcome was calculated as the odds ratio (OR) using a random effects model. Heterogeneity and publication bias were evaluated using the I2 index and the trim-and-fill analysis, respectively. Quality was assessed using the Newcastle-Ottawa scale. The OR for non-Hodgkin lymphoma was increased at 1.22 (95% confidence interval [CI], 1.07-1.39; P < .01) but the OR for Hodgkin lymphoma was not. There was an increased OR for peripheral T-cell lymphoma (OR = 2.42, 95% CI, 1.24-4.72; P = .009) but not for other non-Hodgkin lymphoma subtypes. The OR for leukemia was 1.22 (95% CI, 1.03-1.44; P = .02) and the OR for myeloma was 1.22 (95% CI, 0.98-1.53; P = .08). Although diabetes mellitus type 2 seems to increase the risk of developing lymphoma, leukemia, and myeloma, future studies should focus on evaluating other potential confounders such as obesity, dietary habits, physical activity, and/or antidiabetic therapy.